Metformin and the TAME trial: why the anti-ageing promise still needs proof

Why did scientists get interested in metformin?

Scientists have long investigated whether ageing affects several diseases through shared biological processes. Metformin became a candidate because it is widely used, generally well understood in the people for whom it is prescribed, and influences metabolism.

In a 2016 scientific perspective, Nir Barzilai and colleagues laid out a case for testing the drug against ageing-related outcomes. They described a proposed trial named TAME: Targeting Aging with Metformin.

The important verb is testing. Observations among people who take a medicine for diabetes are not a randomised experiment in otherwise healthy older people. People taking different medicines can differ in health, income, care and many other ways.

What would TAME actually test?

The original TAME proposal describes a multi-centre placebo-controlled study of roughly 3,000 adults aged 65 to 79. Rather than claiming it can measure 'being younger' directly, it would look at the emergence of a cluster of major age-related illnesses and related health outcomes.

That is valuable because a credible anti-ageing intervention should change outcomes that matter to people, not simply a molecular marker in a laboratory.

The sponsor's TAME project information explains the intended design. At the time of this article, we have not identified a published TAME outcomes report demonstrating benefit. Before publication, the editor must reconfirm the latest recruitment and registry status rather than assuming a planned study has already produced results.

What have other human trials found?

The picture is mixed, not a blank cheque. A 2026 randomised trial in 114 older adults with obesity examined whether adding metformin improved an intensive lifestyle programme's effects on physical performance. It did not find an added physical-function improvement when compared with lifestyle treatment plus placebo.

A 2026 systematic review of exercise trials suggested that adding metformin could modestly blunt some fitness and blood-pressure improvements associated with exercise in certain participants. These studies were not direct tests of longevity, and findings should not be applied to everyone taking metformin for a recognised medical need.

These are examples of why biological theories have to survive real-world clinical tests. A drug could still prove helpful in a narrowly defined population without being an all-purpose anti-ageing medicine.

Why do experts disagree?

The optimistic argument is that one drug might affect biological pathways shared across several diseases, potentially making prevention more efficient. The cautious argument is that promising animal experiments, observational patterns and biomarkers regularly fail to translate into benefits in properly controlled human studies.

Both can be true at once: it is reasonable to test the hypothesis, and unreasonable to call it a proven longevity treatment before the trial has answered the relevant questions.

There is also an important distinction between healthspan, the years people spend with good function, and lifespan, the total years lived. A study showing an improvement in one outcome does not automatically establish the other.

Is metformin a healthy-ageing supplement?

No. It is a prescription medicine, and its established indications and risks deserve respect. People should not start or stop it based on articles about TAME. Side effects and medical contraindications require individual clinical assessment.

Even if future work finds a particular ageing-related benefit, it would still matter who was studied, the size of the benefit, the possible harms and whether the result applies to someone without diabetes.

Sources and conflicts

This analysis separates the TAME investigators' design papers, sponsor information and newer controlled human trial results. Researchers proposing a trial are advocates for investigating a hypothesis, not independent proof of its success. Ageless Ape has no relationship with metformin manufacturers or trial sponsors.